- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01311609
A Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
January 31, 2012 updated by: Alcon Research
Multi-Site Post Marketing Surveillance Study for Systane in Indian Patients
This study is a multi-site, unmasked PMS Study.
The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops.
Study Overview
Detailed Description
This study is a multi-site, unmasked PMS Study.
The purpose of the study is to evaluate the physical effects of Systane Lubricant Eye Drops.
The assessed effects include: corneal and conjunctival staining, and ocular signs and symptoms.
This is a two week prospective study.
Study Type
Interventional
Enrollment (Actual)
300
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 18 years of age or older, of both sexes, and any race.
- Willing and able to make all required visits and follow study instructions.
- A sodium fluorescein corneal staining sum of >/ 3 in either eye. A best-corrected visual acuity of 0.6 log MAR or better in each eye as assessed during an ETDRS chart
Exclusion Criteria:
- A history or evidence of ocular or intraocular surgery in either eye within the past 6 months.
- Lasik patients can be included if Lasik surgery was > 6 months prior to the initiation of the study.
- A history of intolerance or hypersensitivity to any component of the study medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Systane
Systane Lubricant Eye Drops
|
Systane Lubricant Eye Drops [1-2 Drops in each eye four times daily (QID)]
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Corneal Staining
Time Frame: Visit 2 (Week 2) - change from baseline
|
Visit 2 (Week 2) - change from baseline
|
|
Best-corrected visual acuity
Time Frame: Visit 2 (Week 2) - change from baseline
|
Visit 2 (Week 2) - change from baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
March 8, 2011
First Submitted That Met QC Criteria
March 8, 2011
First Posted (Estimate)
March 9, 2011
Study Record Updates
Last Update Posted (Estimate)
February 2, 2012
Last Update Submitted That Met QC Criteria
January 31, 2012
Last Verified
January 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-11-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate to Severe Dry Eye
-
Yonsei UniversityRecruitingModerate to Severe Dry EyeKorea, Republic of
-
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical...RecruitingModerate to Severe Dry EyeChina
-
Wenzhou Medical UniversityCompletedEfficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye DiseaseModerate to Severe Dry Eye SyndromeChina
-
University of Illinois at ChicagoJohnson & Johnson Vision Care, Inc.UnknownModerate to Severe Dry Eye DiseaseUnited States
-
Santen SASCompletedModerate to Severe Dry Eye SyndromeFrance
-
Meir Medical CenterUnknownHealthy Subjects | Moderate to Severe Keratoconjunctivitis Sicca (KCS) | Dry Eye Syndrome (DES)
-
Beer, Kenneth R., M.D., PAMedicis Pharmaceutical CorporationCompletedMild to Moderate Temporal Atrophy | Moderate to Severe Glabellar Rhytids | Moderate to Severe Periorbital RhytidsUnited States
-
John C Meyer, MDCompletedMild to Moderate Dry Eye DiseaseUnited States
-
Nanjing RegeneCore Biotech Co., Ltd.Not yet recruiting
-
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.RecruitingModerate to Severe AsthmaChina
Clinical Trials on Systane
-
Alcon ResearchCompleted
-
Gina RogersWithdrawn
-
Innovative MedicalUnknown
-
Southern California College of Optometry at Marshall...Completed
-
Innovative MedicalCompleted
-
University of ChileCompleted
-
Ohio State UniversityAlcon ResearchCompletedEye Diseases | Dry Eye Syndromes | Keratoconjunctivitis Sicca | Lacrimal Apparatus Diseases | Keratoconjunctivitis | Keratitis | Corneal Disease | Ophthalmic SolutionUnited States
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted